PBLA Company Profile and Key Details

PBLA has shown weak momentum, losing -6.72% over the past week and -89.31% over the past quarter, though year-to-date performance is down -93.93%. Short-term trend indicators are bullishly aligned (SMA20 -6.96%, SMA50 -82.02%, SMA200 -96.75%). The stock’s 14-day RSI is 30.77 (weak momentum), while the ATR of 0.45 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.79% below its high and over 4.72% above its low. Average 10-day trading volume of 960.00 shares is below the 3-month average of 4.90 thousand, indicating normal recent market interest.

Panbela Therapeutics, Inc. generated EPS of -$200.81 over the past year. Five-year average earnings growth is 10.22%. The latest quarter delivered EPS of -$1.48. The next quarter is forecast at -$1.23. Next year's EPS is expected at $69.50. Panbela Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 14, 2024, missed forecasts by 22.31%. The prior quarter beat by -28.99%. Over the last six quarters, Apple has recorded several small beats. These include 30.58% in November 09, 2023.

Panbela Therapeutics, Inc. has 4.85 million shares outstanding. The public float is 4.85 million shares, elevated short interest at 3.07% of float. This equals 106.97 thousand shares. The short ratio is 0.07 days. Institutional investors hold 0.16% of the float. Insiders own 0.0%. GOLDMAN SACHS GROUP INC holds 397.95 thousand shares, Schemel Donald Robert has 300.00 thousand shares and Cullen Michael T. has 247.00 thousand shares.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

The stock is currently mid-range between its 52-week high and low $0.00 and $2.50. With a market capitalization of about $53.89 thousand, Panbela Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.88). Key stats such as the average daily volume over the past year has been around 1.05 thousand shares, in line with its 52-week average. Headquartered in Waconia, MN, Panbela Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jennifer K. Simpson, the company employs approximately 7 people and listed since January 03, 2017. Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer.

Our AI price prediction model suggests that Panbela Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.91%, with price expected at $0.01 by May 11, 2026, within a range of $0.00 to $0.02 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by July 24, 2026, with a range of $0.00 to $0.01. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 27, 2027, within a range of $0.00 to $80.99.

Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares are down -93.93% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Panbela Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.19, suggesting 100710.81% upside. Our AI forecast model points to short-term weakness (-9.91% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Panbela Therapeutics, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.01 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.0, also below market averages.